Cystic fibrosis-related diabetes: an update on pathophysiology, diagnosis, and treatment
| Autor: | Cristiano Tulio Maciel Albuquerque, Crésio Alves, Thais DellaManna |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Blood Glucose
medicine.medical_specialty Cystic Fibrosis Endocrinology Diabetes and Metabolism medicine.medical_treatment Cystic fibrosis-related diabetes Cystic Fibrosis Transmembrane Conductance Regulator 030209 endocrinology & metabolism Cystic fibrosis Gastroenterology Diagnostic Techniques Endocrine 03 medical and health sciences 0302 clinical medicine Endocrinology Diabetes mellitus Internal medicine medicine Diabetes Mellitus Humans Mass Screening 030212 general & internal medicine Glycemic Glycated Hemoglobin business.industry Insulin Glucose Tolerance Test medicine.disease Pathophysiology Postprandial Pediatrics Perinatology and Child Health medicine.symptom business Weight gain |
| Zdroj: | Journal of pediatric endocrinologymetabolism : JPEM. 33(7) |
| ISSN: | 2191-0251 |
| Popis: | Cystic fibrosis (CF) is a highly prevalent autosomal recessive disorder that is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene (7q31.2), which encodes the CFTR chloride-anion channel that is expressed in several tissues. Life expectancy has increased significantly over the past few decades due to therapeutic advances and early diagnosis through neonatal screening. However, new complications have been identified, including CF-related diabetes (CFRD). The earliest detectable glycemic abnormality is postprandial hyperglycemia that progresses into fasting hyperglycemia. CFRD is associated with a decline in lung function, impairments in weight gain and growth, pubertal development, and increased morbidity and mortality. Annual screening with oral glucose tolerance test is recommended beginning at the age of 10, and screenings are recommended for any age group during the first 48 h of hospital admission. Fasting plasma glucose levels ≥126 mg/dL (7.0 mmol/L) or 2-h postprandial plasma glucose levels ≥200 mg/dL (11.1 mmol/L) that persist for more than 48 h are diagnostic criteria for CFRD. Under stable health condition, the diagnosis is made when laboratory abnormalities in accordance with the American Diabetes Association criteria are detected for the first time; however, levels of HbA1c |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|